Related references
Note: Only part of the references are listed.Antibodies to watch in 2018
Helene Kaplon et al.
MABS (2018)
Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab
Udupi A. Ramagopal et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies
Mengnan He et al.
ONCOTARGET (2017)
Hallmarks of response to immune checkpoint blockade
Alexandria P. Cogdill et al.
BRITISH JOURNAL OF CANCER (2017)
Cancer immunotherapy by targeting immune checkpoints: mechanism of T cell dysfunction in cancer immunity and new therapeutic targets
Hwei-Fang Tsai et al.
JOURNAL OF BIOMEDICAL SCIENCE (2017)
Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
Jonathan M. Pitt et al.
IMMUNITY (2016)
Modeling bispecific monoclonal antibody interaction with two cell membrane targets indicates the importance of surface diffusion
Bram G. Sengers et al.
MABS (2016)
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Jesse M. Zaretsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Ju Yeon Lee et al.
NATURE COMMUNICATIONS (2016)
Immune Checkpoint Blockade in Cancer Therapy
Michael A. Postow et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities
Barbara Merelli et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2014)
Structure and Interactions of the Human Programmed Cell Death 1 Receptor
Xiaoxiao Cheng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
Andrew M. Intlekofer et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Improving T-cell Immunotherapy for Melanoma Through a Mathematically Motivated Strategy: Efficacy in Numbers?
Natalie Kronik et al.
JOURNAL OF IMMUNOTHERAPY (2012)
A mathematical model of tumor-immune interactions
Mark Robertson-Tessi et al.
JOURNAL OF THEORETICAL BIOLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Mathematical modeling of T-cell activation kinetic
C. Bidot et al.
JOURNAL OF COMPUTATIONAL BIOLOGY (2008)
Mathematical modeling of cancer progression and response to chemotherapy
Sandeep Sanga et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2006)
A validated mathematical model of cell-mediated immune response to tumor growth
LG de Pillis et al.
CANCER RESEARCH (2005)
A theoretical framework for quantitative analysis of the molecular basis of costimulation
A Jansson et al.
JOURNAL OF IMMUNOLOGY (2005)
B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse
T Pentcheva-Hoang et al.
IMMUNITY (2004)
A mathematical model of the effector cell response to cancer
E Allison et al.
MATHEMATICAL AND COMPUTER MODELLING (2004)
Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques
T Keler et al.
JOURNAL OF IMMUNOLOGY (2003)
Molecular coordination of αβ T-cell receptors and coreceptors CD8 and CD4 in their recognition of peptide-MHC ligands
GF Gao et al.
TRENDS IN IMMUNOLOGY (2002)
The interaction properties of costimulatory molecules revisited
AV Collins et al.
IMMUNITY (2002)
Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength
JG Egen et al.
IMMUNITY (2002)
Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses
CC Stamper et al.
NATURE (2001)
Molecular interactions of coreceptor CD8 and MHC class I: the molecular basis for functional coordination with the T-cell receptor
GF Gao et al.
IMMUNOLOGY TODAY (2000)
CD28, CTLA-4 and their ligands: who does what and to whom?
DM Sansom
IMMUNOLOGY (2000)
Share Paper
